Talazoparib
14 interactionsTalazoparib is used to treat certain types of breast cancer that has spread within the breast or to other areas of the body. Talazoparib is in a class of medications called poly (ADP-ribose) polymerase (PARP) inhibitors. It works by stopping or slowing the growth of cancer cells. Read the full Talazoparib drug information page →
Sources: FDA prescribing information (Structured Product Labeling), the published literature cited in each entry, DDInter 2.0 (a major open-access drug-interaction database), and legacy DrugBank interaction data distributed by the NIH's RxNav service (decommissioned in 2024) — analyzed and reviewed by our pharmacist team. How we build this library →
Major
Talazoparib Asciminib Scemblix Increased BCRP substrate exposure and an increased risk of BCRP substrate-related adverse effects Details Talazoparib Capmatinib Tabrecta Increased P-gp substrate exposure and an increased risk of increased adverse reactions Details Talazoparib Cyclosporine Injection Atopica Increased talazoparib exposure and an increased risk of talazoparib-related adverse reactions Details Talazoparib Cyclosporine Ophthalmic Cequa Increased talazoparib exposure and an increased risk of talazoparib-related adverse reactions Details Talazoparib Darolutamide Nubeqa Increased talazoparib exposure and an increased risk of talazoparib-related adverse reactions Details Talazoparib Elacestrant Orserdu Increased talazoparib exposure and an increased risk of talazoparib-related adverse reactions Details Talazoparib Enasidenib Idhifa Increased talazoparib exposure and an increased risk of talazoparib-related adverse reactions Details Talazoparib Febuxostat Uloric Increased talazoparib exposure and an increased risk of talazoparib-related adverse reactions Details Talazoparib Fostamatinib Tavalisse Increased talazoparib exposure and an increased risk of talazoparib-related adverse reactions Details Talazoparib Fostemsavir Rukobia Increased talazoparib exposure and an increased risk of talazoparib-related adverse reactions Details Talazoparib Lenacapavir Injection Sunlenca Increased P-gp substrate exposure and an increased risk of P-gp substrate-related adverse reactions Details Talazoparib Lenacapavir Oral Sunlenca Increased P-gp substrate exposure and an increased risk of P-gp substrate-related adverse reactions Details Talazoparib Leniolisib Joenja Increased BCRP substrate exposure DetailsNo interactions on this page match that filter — try the next page or clear the filter.
Check another drug
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist